HC Wainwright Issues Pessimistic Estimate for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Investment analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Harmony Biosciences in a research note issued on Tuesday, October 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.88 per share for the quarter, down from their prior estimate of $1.00. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.79 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2026 earnings at $0.79 EPS.

Several other research analysts also recently weighed in on HRMY. UBS Group reiterated a “neutral” rating and issued a $37.00 price target on shares of Harmony Biosciences in a research report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $42.00 target price on shares of Harmony Biosciences in a report on Thursday, October 1st. Zacks Research raised shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Weiss Ratings upgraded shares of Harmony Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 12th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Harmony Biosciences in a report on Thursday, October 15th. They set a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.20.

Harmony Biosciences Trading Up 3.0%

Shares of NASDAQ HRMY opened at $37.95 on Wednesday. Harmony Biosciences has a 52-week low of $25.90 and a 52-week high of $43.49. The firm’s 50 day moving average price is $39.78 and its 200-day moving average price is $34.72.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.32. The company had revenue of $261.28 million during the quarter, compared to the consensus estimate of $250.77 million. The company’s revenue was up 30.3% on a year-over-year basis. During the same period last year, the firm posted $0.92 EPS.

Insider Activity

In related news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $43.05, for a total value of $1,543,428.60. Following the transaction, the insider owned 13,115 shares of the company’s stock, valued at $564,600.75. This trade represents a 73.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 72,406 shares of company stock worth $3,108,520 over the last ninety days. 11.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Harmony Biosciences

A number of institutional investors have recently modified their holdings of HRMY. BlackRock Inc. purchased a new stake in shares of Harmony Biosciences in the second quarter valued at approximately $258,583,000. venBio Partners LLC bought a new position in shares of Harmony Biosciences during the 2nd quarter worth $17,192,584. Tieton Capital Management LLC purchased a new position in shares of Harmony Biosciences during the second quarter valued at $11,170,000. Bank of New York Mellon Corp bought a new stake in shares of Harmony Biosciences in the second quarter valued at about $9,937,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Harmony Biosciences by 13.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company’s stock valued at $58,157,000 after acquiring an additional 245,784 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.